Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > By the way posters

<< Previous

Bullboard Posts

Next >>

Comment by jimsenioron Dec 07, 2022 4:44pm

210 Views

Post# 35157462

RE:RE:RE:RE:RE:By the way posters

I have no opinion, but am concerned. You say not encouraging; that suggests some discouraging news. If they are holding discouraging news, they should not have let it trade today. So, I think it is something else.

It would be foolish to wait to release both posters at the same time.

I do not have an answer. Perhaps something technical. Perhaps something good, and they have legal permission to hold it.

Bottom line for me - GOBLET is stellar and will bear fruit at some point.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario